Relationship Between Atypical Pneumonia Agent Antibody Positivity, Laboratory Parameters, and Mortality in COVID-19 Patients
International Journal of Clinical Practice, cilt.2025, sa.1, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 2025 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1155/ijcp/4342794
- Dergi Adı: International Journal of Clinical Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, Directory of Open Access Journals
- Anahtar Kelimeler: atypical pneumonia, COVID-19, prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Objective: Our objective was to analyze the impact of previous infection with atypical pneumonia pathogens on mortality in COVID-19 patients. Materials and Methods: We retrospectively studied complete blood count, procalcitonin, C-reactive protein, D-dimer, ferritin, biochemistry, antibody levels of atypical pneumonia pathogens, and COVID-19 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (PCR) test results in combined (pharyngeal + nasopharyngeal) swab specimens from the airways of patients admitted to the pandemic wards and intensive care units of Adıyaman Training and Research Hospital between 04/01/2020 and 12/31/2021. Patients with positive COVID-19 PCR test results were included in the study. Results: The mean age of the 323 patients was 60.9 ± 18.5 years, and 58.8% were male. When comparing patients with positive and negative antibodies to atypical pneumonia pathogens, we found no differences in mean age, sex, place of hospitalization, length of hospital stay, need for intensive care, and mortality. However, CRP, D-dimer, and ferritin were significantly higher in the group of patients with antibody positivity for atypical pneumonia pathogens (p values 0.008, 0.004, and 0.004). According to the results of multivariate regression analysis in COVID-19 patients with positive antibodies with respect to atypical pneumonia pathogens, a glucose level higher than 148.5, an AST level higher than 26.5, and a lymphocyte count lower than 0.54 were found to be the most important risk factors for mortality in these patients (OR = 2.2, 95% CI 1.1–4.3, and p = 0.048, OR = 3.0, 95% CI 1.2–7.2, and p = 0.015, and OR = 4.1, 95% CI 1.9–8.9, and p < 0.001, respectively). According to the results of multivariate regression analysis, no risk factors for mortality were identified in patients with COVID-19 without positive antibodies against atypical pneumonia pathogens. Conclusion: We found no association between positivity of antibodies of atypical pneumonia pathogens and mortality in COVID-19 patients. However, elevated glucose and AST levels and low lymphocyte count were found to be important risk factors for mortality in COVID-19 patients with positive antibodies against atypical pneumonia pathogens.